Intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention: Rationale and design of the HEBE trial—A prospective, multicenter, randomized trial
To access this article, please choose from the options below
Robin Nijveldt, MD was supported by a grant from The Netherlands Heart Foundation (2003B126).
The study is financially supported by funds provided by the ICIN, the Dutch Heart Foundation, and by unrestricted grants from Biotronik, Boston Scientific, Guerbet, Guidant, Medtronic, Novartis, Pfizer, and Sanofi-Aventis.
PII: S0002-8703(06)00133-5
doi:10.1016/j.ahj.2006.02.007
© 2006 Mosby, Inc. All rights reserved.
